18F-rhPSMA-7 PET用于根治性前列腺切除术后生化复发检测
该回顾性研究纳入261例根治性前列腺切除术后非去势生化复发患者,行18F-rhPSMA-7 PET/CT检查,总检出率为81%。PSA 0.2-<0.5、0.5-<1、1-<2和≥2 ng/mL时检出率分别为71%、86%、86%和95%,PSA<0.2 ng/mL者也有32%存在可疑病灶。既往外照射放疗、6个月内雄激素剥夺治疗及原发Gleason评分不影响检出效能。
要点
- 18F-rhPSMA-7 PET/CT在根治性前列腺切除术后生化复发中总检出率为81%。
- PSA≥2 ng/mL时检出率达95%,PSA 0.2-<0.5 ng/mL时也有71%检出率。
- PSA<0.2 ng/mL患者中32%仍可见可疑复发灶。
核心结论
- 18F-rhPSMA-7 PET/CT在根治性前列腺切除术后早期生化复发中检出率高,尤其在低PSA值患者中。
研究设计与样本
- 回顾性分析2017年6月至2018年3月在本机构连续接受18F-rhPSMA-7 PET/CT的261例根治性前列腺切除术后非去势生化复发患者数据集。
主要发现
- 261例患者中位PSA为0.96 ng/mL(范围0.01-400 ng/mL),中位注射活度为336 MBq,中位摄取时间为76 min。
- 211例(81%)患者18F-rhPSMA-7 PET/CT显示病理性发现。
- PSA 0.2-<0.5、0.5-<1、1-<2和≥2 ng/mL时检出率分别为71%(42/59)、86%(44/51)、86%(42/49)和95%(76/80)。
- PSA<0.2 ng/mL的22例患者中7例(32%)存在可疑病灶。
- 局部复发占43%(113例),盆腔淋巴结转移占42%(110例),腹膜后淋巴结转移占17%(45例),膈上淋巴结转移占8.0%(21例),骨转移占21%(54例),内脏转移占3.8%(10例)。
关键数值与推荐
- 检出效能不受既往外照射放疗影响(79.1% vs. 82.1%,P=0.55)。
- 检出效能不受成像前6个月内雄激素剥夺治疗影响(80.6% vs. 80.9%,P=0.54)。
- 检出效能不受原发Gleason评分影响(≤7为77.9% vs. ≥8为82.6%,P=0.38)。
临床怎么用
- 18F-rhPSMA-7 PET/CT可用于根治性前列腺切除术后生化复发患者的再分期,尤其在低PSA水平时仍具较高检出率。
- 对于PSA<0.2 ng/mL的生化复发患者,18F-rhPSMA-7 PET/CT仍可能发现可疑复发灶。
局限性
- 本研究为单中心回顾性分析,结果需前瞻性研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
18F-labeled prostate-specific membrane antigen (PSMA) PET tracers are increasingly used in preference to 68Ga-PSMA-11 for restaging biochemical recurrence (BCR) of prostate cancer. They are associated with longer half-lives, larger-scale production, and lower positron range than their 68Ga-labeled counterparts. Here, we describe the efficacy of an 18F-labeled radiohybrid PSMA, rhPSMA-7, a novel theranostic PSMA-targeting agent for imaging BCR of prostate cancer. Methods: Datasets from 261 consecutive patients with noncastrate BCR after radical prostatectomy who underwent 18F-rhPSMA-7 PET/CT at our institution between June 2017 and March 2018 were reviewed retrospectively. All lesions suspected of being recurrent prostate cancer were recorded. The detection rate for sites of presumed recurrence was correlated with patients' prostate-specific antigen (PSA) level, primary Gleason score, and prior therapy (androgen deprivation therapy and external-beam radiation therapy). Results: The 261 patients had a median PSA level of 0.96 ng/mL (range, 0.01-400 ng/mL). The median injected activity of 18F-rhPSMA-7 was 336 MBq, with a median uptake time of 76 min. In total, 211 patients (81%) showed pathologic findings on 18F-rhPSMA-7 PET/CT. The detection rates were 71% (42/59), 86% (44/51), 86% (42/49), and 95% (76/80) at PSA levels of 0.2 to <0.5 ng/mL, 0.5 to <1 ng/mL, 1 to <2 ng/mL, and ≥2 ng/mL, respectively. In 32% patients (7/22) with a PSA of less than 0.2 ng/mL, suggestive lesions were present. 18F-rhPSMA-7 PET/CT revealed local recurrence in 43% of patients (113). Lymph node metastases were present in the pelvis in 42% of patients (110), in the retroperitoneum in 17% (45), and in a supradiaphragmatic location in 8.0% (21). Bone and visceral metastases were detected in 21% (54) and 3.8% (10), respectively. Detection efficacy was not influenced by prior external-beam radiation therapy (79.1% vs. 82.1%, P = 0.55), androgen deprivation therapy within the 6 mo preceding imaging (80.6% vs. 80.9%, P = 0.54), or primary Gleason score (77.9% for ≤7 vs. 82.6% for ≥8, P = 0.38). Conclusion:18F-rhPSMA-7 PET/CT offers high detection rates in early BCR after radical prostatectomy, especially among patients with low PSA values.
引用
- Eiber M, Kroenke M, Wurzer A, et al. 18F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. J Nucl Med. 2019. PMID: 31836682. doi:10.2967/jnumed.119.234914
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。